- TLX ยท Nasdaq
- Pharmaceutical Preparations
- North Melbourne, C3
- CIK 0002007191
Updated from SEC filings through
Top things to know
Executives
-
Christian Behrenbruch MD & Group CEO Form 4, May 6, 2026 -
Darren Charlton Smith Group Chief Financial Officer Form 4, September 14, 2026 - Darren Joel Patti Group Chief Operating Officer Form 3, April 1, 2026
- David Norman Cade Group Chief Medical Officer Form 3, April 1, 2026
Telix Pharmaceuticals Ltd is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in North Melbourne, C3. It trades as TLX on Nasdaq. Revenue was $804M in the fiscal year ending December 31, 2025, +55.6% from the year before.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $804M 20-F, 2026-02-20 | $517M 20-F, 2026-02-20 | $333M 20-F, 2026-02-20 |
| Operating income | $29.8M 20-F, 2026-02-20 | $55.2M 20-F, 2026-02-20 | $11.0M 20-F, 2026-02-20 |
| SG&A | Not on file | Not on file | Not on file |
| Net income | -$7.1M 20-F, 2026-02-20 | $33.7M 20-F, 2026-02-20 | $4.2M 20-F, 2026-02-20 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| | MD & Group CEO | Form 4, May 6, 2026 |
| | Group Chief Financial Officer | Form 4, September 14, 2026 |
| Darren Joel Patti | Group Chief Operating Officer | Form 3, April 1, 2026 |
| David Norman Cade | Group Chief Medical Officer | Form 3, April 1, 2026 |
What Telix Pharmaceuticals Ltd does
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. Page 4 29 Telix ASX disclosure September 1, 2026.
Press release "About" paragraph, 10-K for the year ending October 20, 2026
Shares and governance
| Shares outstanding | 338.8 million (as of December 31, 2025) | 20-F/A, March 20, 2026 |
|---|---|---|
| Auditor | PricewaterhouseCoopers (Melbourne, Australia) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 7, 2026 | Darren Charlton Smith Group Chief Financial Officer | Buy | 2,071 | $20K | Form 4, September 14, 2026 |
| April 29, 2026 | Christian Behrenbruch MD & Group CEO | Buy | 67,935 | $997K | Form 4, May 6, 2026 |
Recent 8-K events
No 8-K filings on file.
Frequently asked questions about Telix Pharmaceuticals Ltd
- What does Telix Pharmaceuticals Ltd do?
- In its own words, from Item 1 of its 10-K: "Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. Page 4 29 Telix ASX disclosure September 1, 2026."
- What is Telix Pharmaceuticals Ltd's revenue?
- $804M for the fiscal year ending December 31, 2025, from its 20-F filed February 20, 2026.
- Is Telix Pharmaceuticals Ltd profitable?
- Telix Pharmaceuticals Ltd reported net income of -$7.1M for the fiscal year ending December 31, 2025.
- Who is the CFO of Telix Pharmaceuticals Ltd?
- Darren Charlton Smith, Group Chief Financial Officer, as named in a 4 filed September 14, 2026.
- Where is Telix Pharmaceuticals Ltd headquartered?
- North Melbourne, C3.
- What is Telix Pharmaceuticals Ltd's stock ticker?
- TLX, TLPPF on Nasdaq.
- What industry is Telix Pharmaceuticals Ltd in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Telix Pharmaceuticals Ltd's website?
- telixpharma.com.
- Is Telix Pharmaceuticals Ltd a public company?
- Yes. Telix Pharmaceuticals Ltd files with the SEC under CIK 0002007191 and trades as TLX.
- Who audits Telix Pharmaceuticals Ltd?
- PricewaterhouseCoopers, Melbourne, Australia, as named in its latest annual report (10-K).
- How many shares of Telix Pharmaceuticals Ltd are outstanding?
- 338.8 million shares as of December 31, 2025, from its 20-F/A filed March 20, 2026.
- Have Telix Pharmaceuticals Ltd insiders traded stock recently?
- Since April 29, 2026, officers and directors reported 0 open-market sales and 2 purchases worth about $1.0M on Forms 4 and 5. The most recent: Darren Charlton Smith (Group Chief Financial Officer) bought 2,071 shares on September 7, 2026.